MSD与Promega合作开发Keytruda伴侣诊断,以判断哪些患者会受益于PD-1抑制剂的治疗

2019-11-09 不详 MedSci原创

MSD宣布与Promega(一家为生命科学行业提供解决方案和技术支持的公司)达成新协议,以开发微卫星不稳定性(MSI)技术,用作实体肿瘤伴侣诊断(CDx),与MSD的抗癌药Keytruda(派姆单抗)一起使用。

MSD宣布与Promega(一家为生命科学行业提供解决方案和技术支持的公司)达成新协议,以开发微卫星不稳定性(MSI)技术,用作实体肿瘤伴侣诊断(CDx),与MSD的抗癌药Keytruda(派姆单抗)一起使用。

最近,GlobalData预测,到2023年,免疫肿瘤学的重磅炸弹Keytruda将成为最畅销的药物,到2025年将达到222亿美元,并超过AbbVie和Eisai Co的抗炎药Humira(阿达木单抗),后者目前是世界上销量最大的药品。

Promega公司高级研究科学家Jeff Bacher说,与其他基于DNA的分子筛查方法不同,Promega MSI技术使用"美国国家癌症研究所推荐的五种单态单核苷酸"。

该技术已经在世界各地的实验室中得到验证,可以表征实体瘤MSI的状态。它通过功能性地测量由某些类型的实体瘤中发生的错配修复系统(dMMR)不足引起的插入或缺失(INDEL)。

杰夫继续说,该测试使用"灵敏且特异的标记物组来检测MSI状态,并提供宝贵的见解,以帮助医生了解如何最好地治疗癌症患者,包括可能受益于免疫检查点抑制剂治疗的患者。"

除了与MSD合作外,Promega还宣布计划在美国,中国和欧洲寻求针对MSI体外诊断(IVD)测试的监管许可,该产品计划于2020年上半年推出。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2020095, encodeId=060220200959f, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Oct 19 19:18:00 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791509, encodeId=667c1e9150927, content=<a href='/topic/show?id=45c414e3178' target=_blank style='color:#2F92EE;'>#Promega#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14731, encryptionId=45c414e3178, topicName=Promega)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 29 03:18:00 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852173, encodeId=dc4818521e3b2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 02 00:18:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278940, encodeId=b7a212e8940ef, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527018, encodeId=211c152e01865, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602210, encodeId=940e1602210c4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615860, encodeId=f6571615860c4, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375005, encodeId=8e873e500568, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:13 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375004, encodeId=09c83e50044a, content=很好的朋友, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:04 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2020095, encodeId=060220200959f, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Oct 19 19:18:00 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791509, encodeId=667c1e9150927, content=<a href='/topic/show?id=45c414e3178' target=_blank style='color:#2F92EE;'>#Promega#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14731, encryptionId=45c414e3178, topicName=Promega)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 29 03:18:00 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852173, encodeId=dc4818521e3b2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 02 00:18:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278940, encodeId=b7a212e8940ef, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527018, encodeId=211c152e01865, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602210, encodeId=940e1602210c4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615860, encodeId=f6571615860c4, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375005, encodeId=8e873e500568, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:13 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375004, encodeId=09c83e50044a, content=很好的朋友, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:04 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2020095, encodeId=060220200959f, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Oct 19 19:18:00 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791509, encodeId=667c1e9150927, content=<a href='/topic/show?id=45c414e3178' target=_blank style='color:#2F92EE;'>#Promega#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14731, encryptionId=45c414e3178, topicName=Promega)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 29 03:18:00 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852173, encodeId=dc4818521e3b2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 02 00:18:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278940, encodeId=b7a212e8940ef, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527018, encodeId=211c152e01865, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602210, encodeId=940e1602210c4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615860, encodeId=f6571615860c4, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375005, encodeId=8e873e500568, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:13 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375004, encodeId=09c83e50044a, content=很好的朋友, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:04 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2020-02-02 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=2020095, encodeId=060220200959f, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Oct 19 19:18:00 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791509, encodeId=667c1e9150927, content=<a href='/topic/show?id=45c414e3178' target=_blank style='color:#2F92EE;'>#Promega#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14731, encryptionId=45c414e3178, topicName=Promega)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 29 03:18:00 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852173, encodeId=dc4818521e3b2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 02 00:18:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278940, encodeId=b7a212e8940ef, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527018, encodeId=211c152e01865, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602210, encodeId=940e1602210c4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615860, encodeId=f6571615860c4, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375005, encodeId=8e873e500568, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:13 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375004, encodeId=09c83e50044a, content=很好的朋友, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:04 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2020095, encodeId=060220200959f, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Oct 19 19:18:00 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791509, encodeId=667c1e9150927, content=<a href='/topic/show?id=45c414e3178' target=_blank style='color:#2F92EE;'>#Promega#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14731, encryptionId=45c414e3178, topicName=Promega)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 29 03:18:00 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852173, encodeId=dc4818521e3b2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 02 00:18:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278940, encodeId=b7a212e8940ef, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527018, encodeId=211c152e01865, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602210, encodeId=940e1602210c4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615860, encodeId=f6571615860c4, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375005, encodeId=8e873e500568, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:13 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375004, encodeId=09c83e50044a, content=很好的朋友, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:04 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2019-11-11 zhangj7112
  6. [GetPortalCommentsPageByObjectIdResponse(id=2020095, encodeId=060220200959f, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Oct 19 19:18:00 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791509, encodeId=667c1e9150927, content=<a href='/topic/show?id=45c414e3178' target=_blank style='color:#2F92EE;'>#Promega#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14731, encryptionId=45c414e3178, topicName=Promega)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 29 03:18:00 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852173, encodeId=dc4818521e3b2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 02 00:18:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278940, encodeId=b7a212e8940ef, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527018, encodeId=211c152e01865, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602210, encodeId=940e1602210c4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615860, encodeId=f6571615860c4, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375005, encodeId=8e873e500568, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:13 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375004, encodeId=09c83e50044a, content=很好的朋友, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:04 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2019-11-11 sunylz
  7. [GetPortalCommentsPageByObjectIdResponse(id=2020095, encodeId=060220200959f, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Oct 19 19:18:00 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791509, encodeId=667c1e9150927, content=<a href='/topic/show?id=45c414e3178' target=_blank style='color:#2F92EE;'>#Promega#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14731, encryptionId=45c414e3178, topicName=Promega)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 29 03:18:00 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852173, encodeId=dc4818521e3b2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 02 00:18:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278940, encodeId=b7a212e8940ef, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527018, encodeId=211c152e01865, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602210, encodeId=940e1602210c4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615860, encodeId=f6571615860c4, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375005, encodeId=8e873e500568, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:13 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375004, encodeId=09c83e50044a, content=很好的朋友, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:04 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2020095, encodeId=060220200959f, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Oct 19 19:18:00 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791509, encodeId=667c1e9150927, content=<a href='/topic/show?id=45c414e3178' target=_blank style='color:#2F92EE;'>#Promega#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14731, encryptionId=45c414e3178, topicName=Promega)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 29 03:18:00 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852173, encodeId=dc4818521e3b2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 02 00:18:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278940, encodeId=b7a212e8940ef, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527018, encodeId=211c152e01865, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602210, encodeId=940e1602210c4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615860, encodeId=f6571615860c4, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375005, encodeId=8e873e500568, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:13 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375004, encodeId=09c83e50044a, content=很好的朋友, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:04 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2019-11-10 一天没事干

    很好的学习机会

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2020095, encodeId=060220200959f, content=<a href='/topic/show?id=9a7f14e277b' target=_blank style='color:#2F92EE;'>#PROM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14727, encryptionId=9a7f14e277b, topicName=PROM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Mon Oct 19 19:18:00 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791509, encodeId=667c1e9150927, content=<a href='/topic/show?id=45c414e3178' target=_blank style='color:#2F92EE;'>#Promega#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14731, encryptionId=45c414e3178, topicName=Promega)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 29 03:18:00 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852173, encodeId=dc4818521e3b2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Feb 02 00:18:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278940, encodeId=b7a212e8940ef, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527018, encodeId=211c152e01865, content=<a href='/topic/show?id=1a72122e58c' target=_blank style='color:#2F92EE;'>#MSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12275, encryptionId=1a72122e58c, topicName=MSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b75211789652, createdName=zhangj7112, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602210, encodeId=940e1602210c4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615860, encodeId=f6571615860c4, content=<a href='/topic/show?id=5882260898d' target=_blank style='color:#2F92EE;'>#伴侣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26089, encryptionId=5882260898d, topicName=伴侣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b3b19689320, createdName=ms3892185887221420, createdTime=Mon Nov 11 01:18:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375005, encodeId=8e873e500568, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:13 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375004, encodeId=09c83e50044a, content=很好的朋友, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun Nov 10 09:32:04 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2019-11-10 一天没事干

    很好的朋友

    0

相关资讯

默沙东HIV新药Delstrigo和Pifeltro获得FDA批准上市

MSD的HIV药物Delstrigo和Pifeltro被FDA批准用于没有抗逆转录病毒治疗经验的成年患者。

Genome Biol:严重腹泻相关新细菌的研究

目前,由美国马里兰大学帕克分校和马里兰大学医学院带领的一个研究小组,发现了可触发腹泻病的微生物,以及其他能防御腹泻病的微生物。在以前,这些微生物与这种疾病之间并没有广泛的联系。这项研究未来有望帮助控制发展中国家儿童的一个主要死亡原因。马里兰大学医学院的流行病学和公共卫生学教授O. Colin Stine指出:“我们能够识别这些微生物之间的相互作用,而这些相互作用在以